New diabetes drug shows promise in lowering blood sugar
NCT ID NCT00628212
First seen Jan 05, 2026 · Last updated May 14, 2026 · Updated 20 times
Summary
This study tested a new once-daily pill called MP-513 (Teneligliptin) in 324 Japanese adults with type 2 diabetes. The goal was to see if it safely lowers blood sugar levels (HbA1c) over 12 weeks compared to a placebo. Participants were on diet and exercise alone before starting the study. The results will help determine the right dose for future larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Takikawa-shi, Hokkaido, Japan
Conditions
Explore the condition pages connected to this study.